emmeline lagrange

Dr. emmeline lagrange

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 November 2020 in Blood
Verified
Journal Article
Closed access
PDF file
MCMarie Le Cann
Marie Le Cann
FBFrançoise Bouhour
Françoise Bouhour
KVKarine Viala
Karine Viala
LSLaurence Simon
Laurence Simon
CTCéline Tard
Céline Tard
DRDamien Roos-Weil
Damien Roos-Weil
CANOMAD (chronic ataxic neuropathy, ophthalmoplegia, immunoglobulin M [IgM] paraprotein, cold agglutinins, and disialosyl antibodies) is a rare syndrome characterized by chronic neuropathy with sensory ataxia, ocular, and/or bulbar motor weakness in the presence of a monoclonal IgM reacting against gangliosides containing disialosyl epitopes. Data regarding associated hematologic malignancies and effective therapies in CANOMAD are scarce. We conducted a French multicenter retrospective study that included 45 patients with serum IgM antibodies reacting against disialosyl epitopes in the context of evocating neurologic symptoms. The main clinical features were sensitive symptoms (ataxia, paresthesia, hypoesthesia; n = 45, 100%), motor weakness (n = 18, 40%), ophthalmoplegia (n = 20, 45%), and bulbar symptoms (n = 6, 13%). Forty-five percent of the cohort had moderate to severe disability (modified Rankin score, 3-5). Cold agglutinins were identified in 15 (34%) patients. Electrophysiologic studies showed a demyelinating or axonal pattern in, respectively, 60% and 27% of cases. All patients had serum monoclonal IgM gammopathy (median, 2.6 g/L; range, 0.1-40 g/L). Overt hematologic malignancies were diagnosed in 16 patients (36%), with the most frequent being Waldenström macroglobulinemia (n = 9, 20%). Forty-one patients (91%) required treatment of CANOMAD. Intravenous immunoglobulins (IVIg) and rituximab-based regimens were the most effective therapies with, respectively, 53% and 52% of partial or better clinical responses. Corticosteroids and immunosuppressive drugs were largely ineffective. Although more studies are warranted to better define the optimal therapeutic sequence, IVIg should be proposed as the standard of care for first-line treatment and rituximab-based regimens for second-line treatment. These compiled data argue for CANOMAD to be included in neurologic monoclonal gammopathy of clinical significance.

29 July 2020 in Toxins
Verified
Journal Article
Open access
PDF file
ELemmeline lagrange
emmeline lagrange
Jean-Paul VernouxJean-Paul Vernoux
Jean-Paul Vernoux
Recently, consumption of the gyromitrin-containing neurotoxic mushroom Gyromitra sp. (false morel), as gourmet food was hypothesized to play a role in sporadic amyotrophic lateral sclerosis genesis. The present review analyses recent data on edibility and toxicity of false and true morels and Agaricus spp. Controversy about the toxic status of Gyromitra esculenta was due to variable toxin susceptibility within consumers. We suggest that Verpa bohemica, another false morel, is also inedible. We found a temporary neurological syndrome (NS) with cerebellar signs associated with high consumption of fresh or dried true morels Morchella sp. After ingestion of crude or poorly cooked fresh or dried morels, a gastrointestinal “haemolytic” syndrome was also observed. Agaritine, a water soluble hydrazinic toxin closely related to gyromitrin is present along with metabolites including diazonium ions and free radicals, in Agaricus spp. and A. bisporus, the button mushroom, and in mice after ingestion. It is a potential weak carcinogen in mice, but although no data are available for humans, a lifetime low cumulative extra cancer risk in humans can be estimated to be about 10−5. To conclude, a safety measure is to avoid consuming any true morels or button mushrooms when crude or poorly cooked, fresh or dried.

25 May 2014 in Analytical and Bioanalytical Chemistry
Verified
Journal Article
Closed access
PDF file
BGBMAALS group
BMAALS group
ACAudrey Combès
Audrey Combès
SASaïda El Abdellaoui
Saïda El Abdellaoui
JVJerome Vial
Jerome Vial
ELemmeline lagrange
emmeline lagrange
Valérie PichonValérie Pichon
Valérie Pichon

29 August 2023 in Neurology
Verified
Journal Article
Closed access
PDF file
CLClaire Lefeuvre
Claire Lefeuvre
MAMarie DE Antonio
Marie DE Antonio
FBFrancoise Bouhour
Francoise Bouhour
CTCeline Tard
Celine Tard
ESEmmanuelle Salort-Campana
Emmanuelle Salort-Campana
FGfor Pompe Study Group
for Pompe Study Group
Background and objectives: The French Pompe disease registry was created in 2004, for studies of the natural course of the disease in patients. It rapidly became a major tool for assessing the long-term efficacy of enzyme replacement therapy (ERT) following the market release of alglucosidase-alfa. Methods: Almost 10 years after publication of the baseline characteristics of the 126 patients of the initial French Late-Onset Pompe Disease registry, we provide here an update of the clinical and biological features of patients included in this registry. Results: We describe 210 patients followed at 31 hospital-based French neuromuscular or metabolic centers. Median age at inclusion was 48.67 ± 14.91 years. The first symptom was progressive lower limb muscle weakness, either isolated (50%) or associated with respiratory symptoms (18%), at a median age of 38 ± 14.9 years. At inclusion, 64% of the patients were able to walk independently, and 14% needed a wheelchair. Positive associations were found between Motor Function Measure, Manual Motor Test, and 6-Minute-Walk Test results, and these parameters were inversely associated with the time taken to sit up from a lying position at inclusion. Seventy-two patients had been followed for at least 10 years in the registry. Thirty-three patients remained untreated, a median of 12 years after symptom onset. The standard ERT dose was administered for 177 patients. Discussion: This update confirms previous findings for the adult population included in the French Pompe disease registry, but with a lower clinical severity at inclusion, suggesting that this rare disease is now diagnosed earlier, thanks to greater awareness among physicians. The 6MWT remains an important method for assessing motor performance and walking ability. The French Pompe disease registry provides an exhaustive, nationwide overview of Pompe disease, and can be used to assess individual and global responses to future treatments.

20 July 2019 in Marine Drugs
Verified
Journal Article
Open access
PDF file
NDnicolas delcourt
nicolas delcourt
ELemmeline lagrange
emmeline lagrange
EAEric Abadie
Eric Abadie
VFValerie Fessard
Valerie Fessard
JFJean-Marc Frémy
Jean-Marc Frémy
Cesar MatteiCesar Mattei
Cesar Mattei
Pinnatoxins (PnTXs) are emerging neurotoxins that were discovered about 30 years ago. They are solely produced by the marine dinoflagellate Vulcanodinium rugosum, and may be transferred into the food chain, as they have been found in various marine invertebrates, including bivalves. No human intoxication has been reported to date although acute toxicity was induced by PnTxs in rodents. LD50 values have been estimated for the different PnTXs through the oral route. At sublethal doses, all symptoms are reversible, and no neurological sequelae are visible. These symptoms are consistent with impairment of central and peripheral cholinergic network functions. In fact, PnTXs are high-affinity competitive antagonists of nicotinic acetylcholine receptors (nAChRs). Moreover, their lethal effects are consistent with the inhibition of muscle nAChRs, inducing respiratory distress and paralysis. Human intoxication by ingestion of PnTXs could result in various symptoms observed in episodes of poisoning with natural nAChR antagonists. This review updates the available data on PnTX toxicity with a focus on their mode of action on cholinergic networks and suggests the effects that could be extrapolated on human physiology.

8 April 2024 in European Journal of Neurology
Verified
Journal Article
Open access
CTCéline Tard
Céline Tard
FBFrançoise Bouhour
Françoise Bouhour
MMMaud Michaud
Maud Michaud
SBStephane Beltran
Stephane Beltran
MFMaxime Fournier
Maxime Fournier
PLPascal Laforêt
Pascal Laforêt
Introduction: Late‐onset Pompe disease (LOPD) is characterized by a progressive myopathy resulting from a deficiency of acid α‐glucosidase enzyme activity. Enzyme replacement therapy has been shown to be effective, but long‐term treatment results vary. Avalglucosidase alfa demonstrated non‐inferiority to alglucosidase alfa in a phase 3 study, allowing in France compassionate access for advanced LOPD patients unresponsive to alglucosidase alfa.Methods: Data from the French Pompe registry were analyzed for patients who benefited from a switch to avalglucosidase alfa with at least 1 year of follow‐up. Respiratory (forced vital capacity [FVC]) and motor functions (Six‐Minute Walk Test [6MWT]) were assessed before and 1 year after switching. Individual changes in FVC and 6MWT were expressed as slopes and statistical analyses were performed to compare values.Results: Twenty‐nine patients were included (mean age 56 years, 11 years of prior treatment). The FVC and 6MWT values remained stable. The individual analyses showed a stabilization of motor worsening: –1 m/year on the 6MWT after the switch versus –63 m/year the year before the switch (i.e., a worsening of 33%/year before vs. an improvement of 3%/year later). Respiratory data were not statistically different.Discussion: At the group level, gait parameters improved slightly with a stabilization of previous worsening, but respiratory parameters showed limited changes. At the individual level, results were discordant, with some patients with a good motor or respiratory response and some with further worsening.Conclusion: Switching to avalglucosidase alfa demonstrated varied responses in advanced LOPD patients with failing alglucosidase alfa therapy, with a general improvement in motor stabilization.